Abstract

MSK is committed to the discovery and development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The mission of the Organic Synthesis Core is to provide chemical synthesis services to Center members through a state-of-the art facility staffed by expert professional personnel in chemical synthesis. The Core operates at the interface of chemistry, biology, and medicine, and has the capability of supporting medicinal chemistry efforts to produce and evolve lead candidates and tool compounds in support of Center investigators. The work of the Core has greatly facilitated preclinical studies at the Center. The Core synthesizes novel molecules that are not readily available, by either following described procedures, or by developing new and more suitable methods of synthesis.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084824
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Seo, S K; Gedrimaite, Z; Paskovaty, A et al. (2018) Impact of QuickFISH in addition to antimicrobial stewardship on vancomycin use and resource utilization in cancer patients with coagulase-negative staphylococcal blood cultures. Clin Microbiol Infect 24:1339.e7-1339.e12
McDuff, Susan G R; Chen, Ming-Hui; Renshaw, Andrew A et al. (2018) Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. Cancer 124:1391-1399
Sigel, Carlie S; Krauss Silva, Vitor Werneck; Reid, Michelle D et al. (2018) Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study. Cancer Cytopathol 126:326-335
Fanale, Michelle A; Horwitz, Steven M; Forero-Torres, Andres et al. (2018) Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood 131:2120-2124
Barzilai, Ori; DiStefano, Natalie; Lis, Eric et al. (2018) Safety and utility of kyphoplasty prior to spine stereotactic radiosurgery for metastatic tumors: a clinical and dosimetric analysis. J Neurosurg Spine 28:72-78
Rosenberg, Jonathan B; Kaplitt, Michael G; De, Bishnu P et al. (2018) AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Hum Gene Ther Clin Dev 29:24-47
Ma, Jennifer; Lok, Benjamin H; Zong, Jingfeng et al. (2018) Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. Int J Part Ther 4:10-19
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Garg, Angad; Goldgur, Yehuda; Schwer, Beate et al. (2018) Distinctive structural basis for DNA recognition by the fission yeast Zn2Cys6 transcription factor Pho7 and its role in phosphate homeostasis. Nucleic Acids Res 46:11262-11273
Scordo, Michael; Shah, Gunjan L; Kosuri, Satyajit et al. (2018) Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 24:133-141

Showing the most recent 10 out of 8799 publications